Mostrando 2 resultados de: 2
Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma
ArticleAbstract: NeuGc-containing gangliosides have been described in melanoma cells and are an attractive target forPalabras claves:Clinical trial, Ganglioside, melanoma, N-glycolyl GM3, Therapeutic vaccineAutores:Ávila Y., Carmen Elena Viada, Carr A., Cepeda M., De La Torre A.V., Fernandez L.E., Gracia E., Hernandez J., Osorio M., Pérez K., Reigosa E., Rodríguez M., Saurez G.Fuentes:scopusImmunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy
ArticleAbstract: This study aimed to investigate the immunogenicity of a cancer vaccine consisting of the NeuGcGM3 gaPalabras claves:adjuvant therapy, Breast Cancer, cytotoxic antibodies, Ganglioside, NeuGcGM3, VaccineAutores:Curbelo I., Estevez A., Fernandez L.E., Gonzalez Z., Luaces P.L.o., Mazorra Z., Mulens V., Pérez K., Rubio M.C., Tania Crombet, Valdes-Zayas A., Vega A.M.Fuentes:scopus